Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial-Reference-Cited by-同舟云学术

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial

Published:2002-12 Issue:12 Volume:46 Page:3143-3150
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Choy E. H. S.,Isenberg D. A.,Garrood T.,Farrow S.,Ioannou Y.,Bird H.,Cheung N.,Williams B.,Hazleman B.,Price R.,Yoshizaki K.,Nishimoto N.,Kishimoto T.,Panayi G. S.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference26 articles.

1. Long-Term Outcomes in Rheumatoid Arthritis

2. Management of rheumatoid arthritis. In: editors. Textbook of rheumatology. Philadelphia: WB Saunders; 1993. p. 912.

3. Interleukin-6 and its receptor in autoimmunity

4. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

5. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

Cited by 459 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenic role of anti‐nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases;Immunological Reviews;2024-09-09

2. Il-6 signaling exacerbates hallmarks of chronic tendon disease by stimulating reparative fibroblasts;2024-08-20

3. Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set;Annals of the Rheumatic Diseases;2024-05-22

4. Impact of Obesity on Response Rate for Biological Agents in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies;J BIOL REG HOMEOS AG;2024

5. Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling;Cell Reports;2024-05